Results 191 to 200 of about 24,824,508 (325)

Going viral − Virus‐targeting nanobodies for research, diagnostics and therapy

FEBS Letters, EarlyView.
The increasing prevalence of viral diseases represents a major threat for global human health. Nanobodies, small binding fragments derived from camelid heavy‐chain antibodies, offer versatile tools for viral research, diagnostics, and antiviral therapy.
Domenic Ebert, Ulrich Rothbauer
wiley   +1 more source

Recommendations for the use of clinical outcome assessments in rare disease drug development. [PDF]

EClinicalMedicine
Aiyegbusi OL, McCorry NK, Calvert MJ, Peipert JD, Rivera SC, Muni-Lofra R, Alexis S, Awan F, Bailey T, Billingham L, Callaghan R, Collins C, Currie BM, Dixon M, Duddridge M, Ennis J, Fred L, Greenwell S, Griffiths C, Hareendran A, Illoh OA, Leeson-Beevers K, Letchemanan K, Lister SP, McCabe C, McFatrich M, McKnight AJ, McLaughlin F, Moldovan R, Murray LT, O'Connor DJ, Oko-Osi H, Oni L, Pritchard KM, Rantell KR, Straub V, Barrett TG, LifeArc Accelerating Rare Disease Trials (ARDT) centreaf, LifeArc Accelerating Rare Disease Trials (ARDT) centre.   +38 more
europepmc   +1 more source

Objectives and outcomes of a clinical trial

Indian Journal of Anaesthesia, 2023
Mukul C Kapoor, Rakhee Goyal
openaire   +3 more sources

Unlocking the potential of cell‐permeable nanobodies for intracellular applications

FEBS Letters, EarlyView.
This review outlines current strategies for delivery of nanobodies into cells and highlights recent examples of functional applications. By addressing and manipulating intracellular targets, these molecules hold great potential for treating cancer, respiratory diseases and neurological disorders, making this a vibrant area of research in the biomedical
Mariona Gené‐Verdés, Luise Franz, Christian P.R. Hackenberger   +2 more
wiley   +1 more source

RETRACTION: Aberrant KIF20A Expression Is Associated with Adverse Clinical Outcome and Promotes Tumor Progression in Prostate Cancer. [PDF]

Dis Markers
Markers D.
europepmc   +1 more source

SGLT2 Inhibition in the Diabetic Kidney-From Mechanisms to Clinical Outcome.

American Society of Nephrology. Clinical Journal, 2017
Erik J. M. van Bommel, M. H. Muskiet, L. Tonneijck, M. Kramer, Max Nieuwdorp, D. V. van Raalte   +5 more
semanticscholar   +1 more source

Tumour–host interactions in Drosophila: mechanisms in the tumour micro‐ and macroenvironment

Molecular Oncology, EarlyView.
This review examines how tumour–host crosstalk takes place at multiple levels of biological organisation, from local cell competition and immune crosstalk to organism‐wide metabolic and physiological collapse. Here, we integrate findings from Drosophila melanogaster studies that reveal conserved mechanisms through which tumours hijack host systems to ...
José Teles‐Reis, Tor Erik Rusten
wiley   +1 more source

Editorial: Liquid biopsy biomarkers for cancer detection, treatment monitoring, and clinical outcome prediction. [PDF]

Front Cell Dev Biol
Kurma K, Eslami-S Z, Earl J.
europepmc   +1 more source

Can we predict the clinical outcome of arthroscopic partial meniscectomy? A systematic review

British Journal of Sports Medicine, 2017
S. Eijgenraam, M. Reijman, S. Bierma-Zeinstra, D. V. van Yperen, D. Meuffels   +4 more
semanticscholar   +1 more source

Hijacking emergency granulopoiesis: Neutrophil ontogeny and reprogramming in cancer

Molecular Oncology, EarlyView.
Neutrophils are highly plastic innate immune cells; their functions in cancer extend beyond the tumour microenvironment. This Review summarises current understanding of neutrophil maturation and heterogeneity and highlights tumour‐induced granulopoiesis as a systemic programme that expands immature, immunosuppressive neutrophils via tumour‐derived ...
Gabriela Marinescu, Yi Feng
wiley   +1 more source